Outcomes for FOLFIRI plus bevacizumab or cetuximab in patients treated with oxaliplatin-based adjuvant therapy: A combined analysis of FIRE-3 and CALGB/SWOG 80405 (Alliance)
European Journal of Cancer · 2025
DOI: 10.1016/j.ejca.2025.115694 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift European Journal of Cancer, 2025. Verfasst von Francesca Battaglin und 22 weiteren Autor:innen. Beteiligte Einrichtung: USC Norris Cancer Center, Los Angeles, CA, United States. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Bevacizumab, Camptothecin, Cetuximab. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Institutes of Health, National Cancer Institute.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- USC Norris Cancer Center, Los Angeles, CA, United States.
- University Hospital Grosshadern, Munich, Germany.
- Department of Hematology, Oncology, and Cancer Immunology (CCM); Charité - Universitaetsmedizin Berlin, Berlin, Germany; DKTK Heidelberg, Partner Site, Berlin, Germany. Electronic address: Sebastian.stintzing@charite.de.
- Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN, United States.
- Department of Biostatistics and Bioinformatics and Duke Cancer Institute-Biostatistics, Duke University, Durham, NC, United States.
- UNC Lineberger Cancer Center, Chapel Hill, NC, United States.
Förderung
- NCI NIH HHS
- National Institutes of Health
- National Cancer Institute
- Genentech
- Pfizer
Zitieren
APA
Battaglin, F., O'Neil, B. H., Stintzing, S., Ou, F. S., Zemla, T. J., Niedzwiecki, D., Innocenti, F., Hochster, H. S., von Weikersthal, L. F., Decker, T., Kiani, A., Vehling-Kaiser, U., Heintges, T., Lerchenmüller, C., Weiss, L., Heinrich, K., Goldberg, R. M., Mayer, R. J., Schilsky, R. L., …, & Heinemann, V. (2025). Outcomes for FOLFIRI plus bevacizumab or cetuximab in patients treated with oxaliplatin-based adjuvant therapy: A combined analysis of FIRE-3 and CALGB/SWOG 80405 (Alliance). European Journal of Cancer. https://doi.org/10.1016/j.ejca.2025.115694
Vancouver
Battaglin F, O'Neil BH, Stintzing S, Ou FS, Zemla TJ, Niedzwiecki D, et al. Outcomes for FOLFIRI plus bevacizumab or cetuximab in patients treated with oxaliplatin-based adjuvant therapy: A combined analysis of FIRE-3 and CALGB/SWOG 80405 (Alliance). European Journal of Cancer. 2025. doi:10.1016/j.ejca.2025.115694
BibTeX
@article{Battaglin2025,
author = {Battaglin, Francesca and O'Neil, Bert H and Stintzing, Sebastian and Ou, Fang-Shu and Zemla, Tyler J and Niedzwiecki, Donna and Innocenti, Federico and Hochster, Howard S and von Weikersthal, Ludwig Fischer and Decker, Thomas and Kiani, Alexander and Vehling-Kaiser, Ursula and Heintges, Tobias and Lerchenmüller, Christian and Weiss, Lena and Heinrich, Kathrin and Goldberg, Richard M and Mayer, Robert J and Schilsky, Richard L and Blanke, Charles D and Venook, Alan P and Lenz, Heinz-Josef and Heinemann, Volker},
title = {Outcomes for FOLFIRI plus bevacizumab or cetuximab in patients treated with oxaliplatin-based adjuvant therapy: A combined analysis of FIRE-3 and CALGB/SWOG 80405 (Alliance)},
journal = {European Journal of Cancer},
year = {2025},
doi = {10.1016/j.ejca.2025.115694}
}
EUVIMED